Patients may decline blood products for religious reasons (most commonly Jehovah's Witnesses) or because of concerns about the risks of allogeneic transfusion
Jehovah's Witnesses are a Christian-based religious movement: ~8.8 million members worldwide, ~145,000 in the UK
They believe blood represents a sacred life force, and taking the blood of another into the body violates God's word
Giving treatment to a patient with capacity without their consent is assault and an infringement of their human rights
Care is built around patient blood management (PBM), which has three pillars:
Optimise pre-operative haemoglobin
Reduce peri-operative blood loss
Enhance physiological tolerance of anaemia
As of September 2026, acceptance of the main blood components is a matter of individual conscience for Jehovah's Witnesses, so never assume refusal and ask each patient about each product.
March 2026: autologous blood
The Governing Body announced that use of a patient's own blood is a matter of individual conscience
This includes pre-operative autologous donation, storage and later reinfusion, which was previously unacceptable
September 2026: primary blood components
Whether to accept the four primary components from another person (red cells, white cells, platelets and plasma) is now a matter of individual conscience
Members may also decide whether to donate blood for use as components or fractions
Members choosing to accept components no longer risk being expelled from the congregation
Transfusion of whole blood remains prohibited
Implications for practice
Almost all UK transfusions use separated components rather than whole blood, so many Witnesses may now accept the majority of routine transfusion products
Establish directly which components and techniques each patient will accept or refuse
Advance decisions completed before the change may no longer reflect the patient's wishes so review them with the patient and complete a new one if needed
Some patients will continue to decline all blood products and a capacitous decision must still be respected
The blood conservation principles below remain relevant to all patients, whatever they accept
*Previously unacceptable; individual conscience since September 2026
**Previously unacceptable; individual conscience since March 2026
Acceptability varies between individuals, so discuss and document each item before anaesthesia
Patients can liaise with the Hospital Liaison Committee for Jehovah's Witnesses if they wish
Adults
Autonomy is a core principle and a capacitous refusal of life-saving treatment must be respected
The Mental Capacity Act 2005 states that patients aged ≥16 years are assumed to have capacity unless proven otherwise
A patient must not be assumed to lack capacity simply because their decision appears unwise
Advance decisions
Can be made by an adult with capacity (≥18 years in England and Wales, ≥16 years in Scotland) to refuse treatment should they lose capacity in future
An advance decision refusing life-sustaining treatment is only valid if:
It is in writing
It is signed by the patient (or by another person in their presence and at their direction)
The signature is made or acknowledged in the presence of a witness, who also signs in the patient's presence
It states that it applies even if the patient's life is at risk
Can be withdrawn at any time by a patient with capacity and withdrawal does not need to be in writing
Children
A child is anyone under 18 years (Children Act 1989)
16 to 17 year olds can consent and are assumed to have capacity
Those ≤15 years may consent if Gillick competent for that specific decision
A Gillick competent child's consent cannot be overridden by those with parental responsibility
However, a child's refusal can be overridden by a person with parental responsibility; seek legal advice
If both child and parents refuse essential treatment:
Ensure all alternatives have been explored
As a last resort apply to the High Court for a Specific Issue Order (Section 8, Children Act 1989) via hospital legal services, with the support of ≥2 consultants; parents should be notified
In an emergency, treat in the child's best interests if two consultants agree that all alternatives have been exhausted
Perioperative Management of the Patient who Declines Blood Products
Identification and planning
Identify patients as early as possible via pre-assessment
Multidisciplinary planning including consultant surgeon, anaesthetist and haematologist ± Hospital Liaison Committee representatives if the patient wishes
Consider lower blood loss alternatives e.g. minimally invasive or endovascular techniques
In some cases the risk of haemorrhage may outweigh the benefit of the procedure so use shared decision-making and document all discussions
Elective cases should be on weekdays with direct consultant anaesthetic and surgical involvement
If cell salvage is acceptable, ensure it is available on the day
Consent and documentation
Discuss with the patient in private so they are not under pressure from family or church members
Have a frank and honest discussion about the consequences of refusing blood products
Complete a written advance decision specifying which products and interventions are acceptable or unacceptable (many centres have a proforma)
Review any community advance decision against legal requirements and the 2026 changes and if in doubt complete a new one
Potential consequences of refusing transfusion
Haemodynamic instability and organ failure
Requirement for mechanical ventilation and unplanned ICU admission
Delayed wound healing and ↑ wound infection
Prolonged hospital stay
↑ mortality
Optimisation
Take a medical and drug history for coagulation disorders and drugs impairing haemostasis
Stop antiplatelet and anticoagulant drugs where clinically appropriate
Optimise red cell mass through investigation of anaemia and correction of deficiencies
Offer iron therapy if Hb <130 g/L, and delay elective surgery until achieved where possible
Oral iron for iron deficiency, low iron stores or iron sequestration
IV iron if oral response is inadequate, oral iron cannot be absorbed or taken, or surgery is within 4 weeks
Recombinant EPO: ↑ Hb and ↓ transfusion requirement but requires specialist advice and only once nutritional deficiencies are excluded or treated
Pre-operative autologous donation may now be an option for some patients
Emergency surgery
Same principles as elective surgery but with time constraints
If the patient lacks capacity, efforts must be made to find an advance decision (the GP may have access)
If no valid advance decision exists, act in the patient's best interests (see major haemorrhage section)
General
MDT review on the day to ensure a valid advance decision is immediately available
Highlight the patient's wishes and the blood conservation plan at the WHO team brief
Anaesthetic strategies
Temperature monitoring and active warming: hypothermia ↓ coagulation enzyme activity and platelet function
Ventilation: avoid hypercapnia (vasodilation) but also excessive airway pressures (↓ venous return, ↑ venous congestion)
Positioning to avoid venous pooling e.g. avoid IVC compression when prone
IV tranexamic acid for any procedure with a risk of moderate blood loss, unless contraindicated
Neuraxial anaesthesia: sympathetic block reduces arterial & venous pressures, contributing to 335ml less blood loss and a 15% ↓ in red cell transfusion vs GA in major abdominal and lower limb surgery
Limit phlebotomy and use paediatric blood bottles
Permissive hypotension
Advantages
Disadvantages
↓ blood flow to the surgical field
Organ hypoperfusion: myocardial, renal and cerebral injury
~287 ml ↓ in mean blood loss in orthopaedic surgery
Mixed evidence; benefit outside orthopaedics not demonstrated
↓ transfusion requirement
Avoid in coronary or cerebrovascular disease, and in Caesarean delivery
Cell salvage
↓ post-operative anaemia and allogeneic transfusion (by 37 to 49% in cardiac, vascular and orthopaedic surgery)
Consider when blood loss may exceed 500 ml
If blood loss is hard to predict, use 'collect only' mode and process only if bleeding becomes significant
Many Witnesses accept the standard set-up although some request a continuous circuit, achieved by connecting the reinfusion bag to a cannula via a saline-primed giving set run slowly until processed blood is available
Contraindictions
There are no absolute contraindications
Contamination with tumour cells, bowel contents or infected fluid although benefits may still outweigh risks
Haemodilution
Acute normovolaemic haemodilution (ANH):
10 to 20% of estimated blood volume withdrawn before induction into an anticoagulated reservoir and replaced with crystalloid or colloid
Blood lost during surgery has a lower haematocrit, so fewer red cells are lost; withdrawn blood is reinfused at the end
~26% ↓ risk of red cell transfusion, although benefit is likely overestimated
Hypervolaemic haemodilution: fluid infused before surgery without removing blood; simpler, but only case reports and small trials support it
Surgical strategies
Meticulous haemostasis by an experienced surgeon is probably the most important factor
Diathermy
Topical haemostatic agents: shorten time to haemostasis but do not ↓ clinically relevant blood loss or transfusion
Arterial tourniquets: ↓ intra-operative loss and improve the surgical field, but no difference in overall blood loss or transfusion
Complications
Systemic: circulatory overload or cardiovascular collapse (sudden changes in SVR), hypercapnia, hyperkalaemia, ↑ VTE risk, altered drug kinetics
Local: nerve, vascular, muscle and skin injury
Close monitoring for bleeding with a low threshold for escalation ± HDU
Handover should specify consent boundaries, intra-operative events and the plan, including timing of VTE prophylaxis
Minimise ongoing blood loss:
Normothermia
Correct coagulopathy
Consider a repeat dose of IV tranexamic acid if concern about bleeding (little evidence over a single dose)
Minimise blood sampling
NSAIDs are unlikely to cause bleeding and can be continued unless otherwise contraindicated
Optimise oxygen delivery and nutrition to support endogenous haemopoiesis
Initial management
Medical management proceeds alongside medicolegal steps, with ≥2 consultant anaesthetists present and contemporaneous documentation
As for any major haemorrhage: call for help, inform theatre team, check IV access, warmed fluids and active warming
Point-of-care testing (blood gas, TEG/ROTEM) and laboratory calcium and fibrinogen using paediatric bottles
Replace calcium and give tranexamic acid
Consultant-led surgical haemostasis; consider interventional radiology for arterial bleeding or difficult access
Early haematology input to guide acceptable products
Blood product alternatives
Agent
Key points
Desmopressin
0.3 μg/kg IV or SC; ↑ factor VIII and vWF; little evidence it ↓ surgical blood loss; risks thrombosis, fluid retention and hyponatraemia
Prothrombin complex concentrate
Reversal of vitamin K antagonists; plasma-derived so may not be acceptable
Recombinant factor VIIa
Not plasma-derived so may be acceptable; UK licence limited to severe PPH, congenital factor VII deficiency and rare bleeding disorders; high thrombotic risk
Fibrinogen concentrate
Plasma-derived; hypofibrinogenaemia is common in major (especially obstetric) haemorrhage; systematic reviews show no overall benefit
Medicolegal steps: patient lacks capacity
E.g. under general anaesthesia
A valid advance decision must be honoured
If no advance decision, act in the patient's best interests:
Make every effort to avoid transfusion if there is reason to believe the patient would refuse
Giving blood products is justified to avoid death or serious harm
Involve legal services if there is doubt about the existence or validity of an advance decision, or dispute about best interests
Medicolegal steps: conscious patient
Consent may be revisited during an evolving crisis; a patient with capacity can revoke an advance decision at any time
Beware coercion (or perceived coercion) and cognitive impairment from sedatives or haemorrhage
A suggested mid-crisis approach:
Optimise the 'environment of autonomy' by managing pain and distress
Assess capacity and ask if the patient feels able to make a choice
Ask the patient to state their choice and articulate its consequences
Two healthcare providers present; document clearly
This practice remains controversial and should be managed with caution
Antenatal
Consultant-led obstetric care and referral to a high-risk obstetric anaesthesia clinic
Optimise Hb, establish acceptable therapies and complete a valid written advance decision
Identify PPH risk factors to inform planning
Intrapartum
Notify the consultant obstetrician and anaesthetist on arrival in labour; both should be present for instrumental or Caesarean delivery in theatre
Early anaesthetic review: confirm advance decision and additional risk factors
Wide-bore IV access and active management of the third stage
Caesarean delivery
Experienced surgical and anaesthetic teams; plan timely uterotonics and consider routine tranexamic acid
Permissive hypotension is not appropriate
Cell salvage recommended if acceptable:
Separate suction for amniotic fluid is no longer considered essential
Leucocyte depletion filters do not remove all amniotic fluid components and can slow reinfusion to ~40 ml/min
Major obstetric haemorrhage
Follow the principles above alongside standard major obstetric haemorrhage guidelines: prompt escalation, early fluid resuscitation, uterotonics and tranexamic acid
Fibrinogen <2 g/L strongly predicts progression to major obstetric haemorrhage (normal at term may be 4 to 7 g/L)
Epidural blood patch
May be unacceptable to some Witnesses
A continuous circuit technique has been described: IV catheter connected to the Tuohy needle via sterile extension tubing and a four-way tap, allowing aspiration and injection
Requires a Luer Tuohy needle, so may not be possible in centres using NRFit devices
Patients may temporarily lack capacity: apply the medicolegal principles above
Acceptability of extracorporeal circuits (RRT, plasma exchange, ECMO) varies and may not have been considered in a community advance decision
If unclear, engage medicolegal services and the patient's family
Non-blood circuit primers may improve acceptability